Law360, New York (July 01, 2008) -- The lead plaintiffs in a shareholder lawsuit over Merck & Co. Inc.'s shelved Vioxx painkiller have asked to assume the role of lead plaintiff in a new proposed multidistrict litigation over allegations that the company covered up evidence that its cholesterol drug Vytorin was less effective than advertised.
In a motion filed last Monday in the U.S. District Court for the District of New Jersey, the plaintiffs asked that Schatz Nobel Izard PC and Schiffrin Barroway Topaz &...
